Drugs / ALVAC-hIL-12
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003556 | Jan 1999 → May 2001 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC-hIL-12 | “a Recombinant Canarypox Virus Encoding Human Interleukin 12 (ALVAC-hIL-12)” NCT00003556 ↗ |
| Modality | Vaccine | “canarypox-hIL-12 melanoma vaccine” NCT00003556 ↗ |
| Route | Other | “Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally” NCT00003556 ↗ |